Introduction
Cardiovascular disease (CVD) is one of the primary causes of mortality
in people with diabetes, accounting for >70% of deaths in
these people.1 Low-dose aspirin is considered the most
widely used agent for preventing cardiovascular
disease.2-4, and its use in subjects with diabetes is
also recommended by various guidelines 5–6. Several
primary prevention aspirin trials, mostly done before 2000, suggested a
reduction in myocardial infarction and stroke, although not
mortality7 but at the cost of increased bleeding
events.8–10 However, the role of Aspirin in the
primary prevention of CVD is still unclear and under debate. According
to guidelines by the American Diabetes Association, the American Heart
Association, and the American College of Cardiology Foundation advocate
using low-dose Aspirin for the primary prevention of CVD in adults with
diabetes, but which should be based on the individual risk of CVD and
risk of bleeding11. Aim: The present
meta-analysis was done to rule out the role of Aspirin in patients with
diabetes and to compare the effectiveness of Aspirin with a placebo (or
no treatment) for the primary prevention of CVD and all-cause mortality
events in people with diabetes.